IL-4 receptor alpha antagonist

0 marketed 2 in Phase 3

This page covers all IL-4 receptor alpha antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-4Rα, IL-4Rα (Interleukin-4 receptor alpha).

Targets

IL-4Rα · IL-4Rα (Interleukin-4 receptor alpha)

Phase 3 pipeline (2)

Tabirafusp tedromer · Kodiak Sciences Inc · Allergy
Tabirafusp tedromer is a fusion protein that targets the interleukin-4 receptor alpha subunit.
GSK3511294 (Depemokimab) · GlaxoSmithKline · Immunology
Depemokimab is a monoclonal antibody that inhibits interleukin-4 receptor alpha (IL-4Rα) to reduce type 2 inflammatory responses.